Remdesivir in COVID-19: A Critical Review of Pharmacology, Pre-clinical and Clinical Studies

Overview

Journal Diabetes Metab Syndr

Specialty Endocrinology

Date 2020 May 20

PMID 32428865

Citations 84

Authors

Awadhesh Kumar Singh

Akriti Singh

Ritu Singh

Anoop Misra

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19.

Methods: We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020 using specific key words such as "Remdesivir" or 'GS-5734″ AND "COVID-19" or "SARS-CoV-2" and retrieved all the article published in English language, that have reported the pharmacology and the clinical outcomes of remdesivir in patients with COVID-19.

Results: Initial compassionate use of remdesivir has shown a fairly good result, but difficult to quantify, in the absence of control arm. While the very first double-blind, placebo-controlled, randomized trial conducted in Wuhan, did not find any significant benefit compared to the control, the preliminary result of another similar multi-country trial has shown a significant faster time to recovery but without any difference in mortality.

Conclusions: Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.

Citing Articles

Limited Short-Term Evolution of SARS-CoV-2 RNA-Dependent RNA Polymerase under Remdesivir Exposure in Upper Respiratory Compartments.

Novitsky V, Beckwith C, Carpenter-Azevedo K, Shin J, Hague J, Sam S Viruses. 2024; 16(10).

PMID: 39459846 PMC: 11512361. DOI: 10.3390/v16101511.

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.

Chen C, Fang J, Chen S, Rajaofera M, Li X, Wang B BMC Infect Dis. 2023; 23(1):672.

PMID: 37814214 PMC: 10563317. DOI: 10.1186/s12879-023-08525-0.

Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study.

Cosaro E, Pires J, Castillo D, Murphy B, Reagan K Viruses. 2023; 15(8).

PMID: 37632022 PMC: 10458979. DOI: 10.3390/v15081680.

evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment.

Pagliarin L, de Oliveira L, Dos Anjos V, de Souza C, Peiter G, Facanha Wendel C World J Biol Chem. 2023; 14(4):72-83.

PMID: 37547340 PMC: 10401403. DOI: 10.4331/wjbc.v14.i4.72.

Potency of Xanthone Derivatives from L. for COVID-19 Treatment through Angiotensin-Converting Enzyme 2 and Main Protease Blockade: A Computational Study.

Suhandi C, Alfathonah S, Hasanah A Molecules. 2023; 28(13).

PMID: 37446849 PMC: 10343608. DOI: 10.3390/molecules28135187.

References

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin J, Sutton S . Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Med. 2020; 1(1):114-127.e3. PMC: 7274588. DOI: 10.1016/j.medj.2020.06.001. View

Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M . Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(4):e208857. DOI: 10.1001/jamanetworkopen.2020.8857. View

Huang M, Li M, Xiao F, Pang P, Liang J, Tang T . Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. Natl Sci Rev. 2021; 7(9):1428-1436. PMC: 7313782. DOI: 10.1093/nsr/nwaa113. View

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323(1):264-8. PMC: 7092815. DOI: 10.1016/j.bbrc.2004.08.085. View

Norrie J . Remdesivir for COVID-19: challenges of underpowered studies. Lancet. 2020; 395(10236):1525-1527. PMC: 7190306. DOI: 10.1016/S0140-6736(20)31023-0. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Barnard D, Day C, Bailey K, Heiner M, Montgomery R, Lauridsen L . Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother. 2006; 17(5):275-84. DOI: 10.1177/095632020601700505. View

10.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

11.

Sheahan T, Sims A, Graham R, Menachery V, Gralinski L, Case J . Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9(396). PMC: 5567817. DOI: 10.1126/scitranslmed.aal3653. View

12.

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

13.

Brown A, Won J, Graham R, Dinnon 3rd K, Sims A, Feng J . Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019; 169:104541. PMC: 6699884. DOI: 10.1016/j.antiviral.2019.104541. View

14.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Sevestre J . Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020; 34:101663. PMC: 7151271. DOI: 10.1016/j.tmaid.2020.101663. View

15.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View

16.

Lo M, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard A . GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017; 7:43395. PMC: 5338263. DOI: 10.1038/srep43395. View

17.

Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E . Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Rep Med. 2020; 1(4):100059. PMC: 7373044. DOI: 10.1016/j.xcrm.2020.100059. View

18.

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59(3):252-6. PMC: 1746980. DOI: 10.1136/thorax.2003.012658. View

19.

Agostini M, Andres E, Sims A, Graham R, Sheahan T, Lu X . Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9(2). PMC: 5844999. DOI: 10.1128/mBio.00221-18. View

20.

de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T . Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020; 117(12):6771-6776. PMC: 7104368. DOI: 10.1073/pnas.1922083117. View